Literature DB >> 24291500

Activation of farnesoid X receptor induces RECK expression in mouse liver.

Xiaomin Peng1, Weibin Wu2, Bo Zhu1, Zhichao Sun1, Lingling Ji1, Yuanyuan Ruan1, Meiling Zhou3, Lei Zhou4, Jianxin Gu2.   

Abstract

Farnesoid X receptor (FXR) belongs to the ligand-activated nuclear receptor superfamily, and functions as a transcription factor regulating the transcription of numerous genes involved in bile acid homeostasis, lipoprotein and glucose metabolism. In the present study, we identified RECK, a membrane-anchored inhibitor of matrix metalloproteinases, as a novel target gene of FXR in mouse liver. We found that FXR agonist substantially augmented hepatic RECK mRNA and protein expression in vivo and in vitro. FXR regulated the transcription of RECK through directly binding to FXR response element located within intron 1 of the mouse RECK gene. Moreover, FXR agonist reversed the down-regulation of RECK in the livers from mice fed a methionine and choline deficient diet. In summary, our data suggest that RECK is a novel transcriptional target of FXR in mouse liver, and provide clues to better understanding the function of FXR in liver.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  FBS; FXR; Farnesoid X receptor; MCD; MMPs; PEPCK; Primary hepatocytes; RECK; RXRα; SHP; SREBP-1c; Transactivation; farnesoid X receptor; fetal bovine serum; matrix metalloproteinases; methionine and choline deficient; phosphoenolpyruvate carboxykinase; retinoid X receptor α; reversion-inducing cysteine rich protein with Kazal motifs; small heterodimer partner; sterol regulatory element-binding protein-1c

Mesh:

Substances:

Year:  2013        PMID: 24291500     DOI: 10.1016/j.bbrc.2013.11.082

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

Review 1.  Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease.

Authors:  Jiao-Ya Xu; Zhong-Ping Li; Li Zhang; Guang Ji
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

Review 2.  Reversion inducing cysteine rich protein with Kazal motifs and cardiovascular diseases: The RECKlessness of adverse remodeling.

Authors:  Jacob J Russell; Laurel A Grisanti; Scott M Brown; Chastidy A Bailey; Shawn B Bender; B Chandrasekar
Journal:  Cell Signal       Date:  2021-03-27       Impact factor: 4.850

3.  Farnesoid X receptor associates with β-catenin and inhibits its activity in hepatocellular carcinoma.

Authors:  Xijun Liu; Xingwang Zhang; Lingling Ji; Jianxin Gu; Meiling Zhou; She Chen
Journal:  Oncotarget       Date:  2015-02-28

Review 4.  The Role of RECK in Hepatobiliary Neoplasia Reveals Its Therapeutic Potential in NASH.

Authors:  Ryan J Dashek; Connor Diaz; Bysani Chandrasekar; R Scott Rector
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-20       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.